The effects of purslane consumption on glycemic control and oxidative stress: A systematic review and dose–response meta‐analysis

Jafari, Naser; Shoaibinobarian, Nargeskhatoon; Dehghani, Azadeh; Rad, Amirhosein; Mirmohammadali, Seyedeh Nooshan; Alaeian, Mohammad Javad; Hamedi, Yasaman; Zamani, Mohamad; Goudarzi, Mohammad Ali; Asbaghi, Omid

doi:10.1002/fsn3.3311

Cited by 12 publications

(3 citation statements)

References 70 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized double-blind controlled clinical trial, individuals who received purslane seed extract had similar fasting and post-prandial blood glucose levels compared to those on metformin treatment [23]. A recent meta-analysis of the effect of purslane on glycemic control in patients with or without T2DM, including 16 randomized controlled trials, reported that purslane consumption significantly reduced FBG but had no effect on HbA1c, fasting insulin, and HOMA-IR [24]. We found that purslane administration significantly reduced fasting insulin and HOMA-IR, but we included a different study population.…”

Section: Discussionmentioning

confidence: 99%

A Pilot Study on the Glucose-Lowering Effects of a Nutritional Supplement in People with Prediabetes

Bemplidakis,

Eleftheriadou,

Kosta

et al. 2023

Diabetology

View full text Add to dashboard Cite

Background and Objectives: Prediabetes is associated with a high risk of developing diabetes and cardiovascular disease. Early treatment with exercise and dietary interventions can reduce the progression of prediabetes to diabetes or even lead to a return of glucose levels to normal. The aim of the study was to evaluate the effect of a dietary supplement with Portulaca oleracea and titrated Cistus creticus extract on the glycemic profile of people with prediabetes. Materials and Methods: Participants were assigned to a dietary supplement with Portulaca oleracea and titrated Cistus creticus extract, along with vitamins and minerals, received once daily for 90 days. Demographics and medical history were obtained, and a complete clinical examination, measurement of somatometric characteristics, and laboratory parameters were performed at baseline. The measurement of somatometric characteristics and laboratory tests were repeated at the end of the study. Results: A total of 26 people with prediabetes participated, 11 females and 15 males. There was a tendency for a decrease in HbA1c after intervention [baseline: 5.9 (5.7–6.1)%; at the end of the study: 5.7 (5.7–6.0)%, p = 0.062] and a significant decrease in fasting glucose levels (from 110.8 ± 7.0 mg/dL to 103.9 ± 10.3, p = 0.005). Fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) decreased significantly [baseline fasting insulin: 20.7 (9.3–34.20) μU/mL; at the end of the study: 15.1 (8.6–19.0) μU/mL, p = 0.028; baseline HOMA-IR: 3.6 (2.5–8.9); at the end of the study: 3.5 (2.0–4.6), p = 0.035]. Significant reductions were observed in alkaline phosphatase and uric acid levels. No significant change was observed in body weight, body mass index, or waist circumference after the intervention. No treatment-emergent adverse events were observed, and all participants completed the study. Conclusions: The dietary supplement from Portulaca oleracea and titrated Cistus creticus extract, along with vitamins and minerals, may improve the metabolic profile of people with prediabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

A Pilot Study on the Glucose-Lowering Effects of a Nutritional Supplement in People with Prediabetes

Bemplidakis,

Eleftheriadou,

Kosta

et al. 2023

Diabetology

View full text Add to dashboard Cite

show abstract

“…Diabetes is also linked to dyslipidemia (7), elevated liver enzymes (8), elevated inflammatory factors (9), polycystic ovarian syndrome (10, 11), and overweight or obesity (12,13). Some factors can modify the relationship between diabetes and CVDs such as lifestyle (14), physical activity (15), dietary intake (16)(17)(18), and pharmacotherapy (19).…”

Section: Introductionmentioning

confidence: 99%

The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials

Zamani,

Nikbaf-Shandiz,

Aali

et al. 2023

Front. Nutr.

Self Cite

View full text Add to dashboard Cite

Acarbose (ACB) seems to be an effective drug in the management of cardiovascular risk factors. However, no previous meta-analysis of randomized controlled trials (RCTs) has been done to evaluate the effects of ACB on cardiovascular risk factors on impaired glucose tolerance (IGT), type 2 diabetes mellitus (T2D), and type 1 diabetes mellitus (T1D). We comprehensively searched electronic databases including Scopus, Web of Science, and PubMed for RCTs for related keywords up to September 2022. A random-effects model was used to estimate the weighted mean difference (WMD) and 95% confidence interval (CI). The pooled analysis demonstrated that ACB treatment had a significant effect on fasting blood glucose (FBG) (WMD = −3.55 mg/dL; 95%CI: −6.29, −0.81; p = 0.011), fasting insulin (WMD = −6.73 pmoL/L; 95%CI: −10.37, −3.10; p < 0.001), HbA1c [WMD = −0.32%; 95%CI: −0.45, −0.20; p < 0.001], body weight (WMD = −1.25 kg; 95%CI: −1.79, −0.75; p < 0.001), body mass index (BMI) (WMD = −0.64 kg/m2; 95%CI: −0.92, −0.37; p < 0.001), tumor necrosis factor-alpha (TNF-α) (WMD = −2.70 pg/mL, 95%CI: −5.25, −0.16; p = 0.037), leptin (WMD = −1.58 ng/mL; 95%CI: −2.82, −0.35; p = 0.012), alanine transaminase (ALT) (WMD = 0.71 U/L; 95%CI: −0.31, 1.85; p = 0.164), triglyceride (TG) (WMD = −13.89 mg/dL; 95%CI: −20.69, −7.09; p < 0.001), total cholesterol (TC) (WMD = −2.26 mg/dL; 95%CI: −4.18, −0.34; p = 0.021), systolic blood pressure (SBP) (WMD = −1.29 mmHg; 95%CI: −2.44, −0.15; p = 0.027), and diastolic blood pressure (DBP) (WMD = 0.02 mmHg; 95%CI: −0.41, 0.45; p = 0.925) in an intervention group, compared with a placebo group. The non-linear dose–response analysis showed that ACB reduces the TC in trial duration by >50 weeks, and 180 mg/day is more effective for the decrement of CRP. ACB can improve lipid profiles, glycemic indices, anthropometric indices, and inflammatory markers in T2D, T1D, and IGT patients.

show abstract

“…Hyperglycemia is a serious condition associated with various adverse consequences and an increased risk of non-communicable diseases, including diabetes, cardiovascular diseases, and metabolic syndrome (Sari & Artsanthia, 2019). Maintaining glycemic control is crucial to prevent chronic complications, especially in patients with diabetes (Fasil, Biadgo & Abebe, 2019;Jafari et al). Lifestyle interventions, such as adopting a healthy diet and engaging in physical activity, have been found to be effective in preventing and managing hyperglycemia and its complications Sampson et al, 2021;…”

Section: Introductionmentioning

confidence: 99%

A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults

Dehkordi

Pahlavani

Nikbaf-Shandiz

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Prior research has yielded mixed results regarding the impact of acarbose intake on glycemic markers. To provide a more comprehensive analysis, a systematic review and meta-analysis was performed to compile data from various randomized controlled trials (RCTs) examining the effects of acarbose intake on fasting blood sugar (FBS), insulin, hemoglobin A1C (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR) in adults. Methods: To identify relevant literature up to April 2023, a comprehensive search was conducted on various scholarly databases, including PubMed, Web of Science, and Scopus databases. The effect size of the studies was evaluated using a random-effects model to calculate the weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity between studies was assessed using Cochran’s Q test and I2. Results: This systematic review and meta-analysis included a total of 101 RCTs with a total of 107 effect sizes. The effect sizes for FBS in milligrams per deciliter (mg/dl), insulin in picomoles per liter (pmol/l), hemoglobin A1C (HbA1c) in percentage (%), and homeostasis model assessment of insulin resistance (HOMA-IR) were 92, 46, 80, and 22, respectively. The pooled analysis indicated that acarbose intake resulted in significant decreases in FBS (p=0.018), insulin (p<0.001), HbA1c (p<0.001), and HOMA-IR (p<0.001). Conclusion: The findings of this systematic review and meta-analysis suggest that acarbose intake can potentially lead to significant improvements in glycemic indices by decreasing the levels of FBS, HbA1c, and insulin. However, larger and more rigorously designed studies are still needed to further evaluate and strengthen this association.

show abstract

The effects of purslane consumption on glycemic control and oxidative stress: A systematic review and dose–response meta‐analysis

Cited by 12 publications

References 70 publications

A Pilot Study on the Glucose-Lowering Effects of a Nutritional Supplement in People with Prediabetes

A Pilot Study on the Glucose-Lowering Effects of a Nutritional Supplement in People with Prediabetes

The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials

A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults

Contact Info

Product

Resources

About